Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
PURPOSE: The randomized PANAMA trial investigated the efficacy of panitumumab (Pmab) when added to maintenance therapy with fluorouracil and folinic acid (FU/FA) in patients with RAS wild-type metastatic colorectal cancer. METHODS: Following first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab, responding patients (stable disease or partial or complete remission) were randomly assigned (1:1, open-label) to maintenance treatment with either FU/FA plus Pmab or FU/FA alone. The primary objective was to demonstrate superiority of progression-free survival (PFS, time from random assignment until progression or death) in favor of FU/FA plus Pmab with a hazard ratio (HR) of 0.75, a power of 80%, and a significance level of 10%. Secondary end points included overall survival, objective response rate of maintenance therapy, and toxicity. Survival end points were analyzed by the Kaplan-Meier method and compared by log-rank test and Cox regressions. Dichotomous variables were compared by Fisher's exact test; odds ratios were indicated when appropriate. The trial is registered with ClinicalTrials.gov ( NCT01991873 ). RESULTS: Overall, 248 patients were randomly assigned and received maintenance therapy with either FU/FA plus Pmab (125 patients) or FU/FA alone (123 patients). At data cutoff, with 218 events (of 218 needed), PFS of maintenance therapy was significantly improved with FU/FA plus Pmab (8.8 months v 5.7 months; HR, 0.72; 80% CI, 0.60 to 0.85; P = .014). Overall survival (event rate 54%) numerically favored the FU/FA plus Pmab arm (28.7 months v 25.7 months; HR, 0.84; 95% CI, 0.60 to 1.18; P = .32). Objective response rates were 40.8% in patients receiving FU/FA plus Pmab versus 26.0% in patients receiving FU/FA alone (odds ratio, 1.96; 95% CI, 1.14 to 3.36; P = .02). The most frequent Common Terminology Criteria for Adverse Event grade ≥ 3 event during maintenance therapy was skin rash (7.2%). CONCLUSION: In RAS wild-type metastatic colorectal cancer, maintenance therapy with FU/FA plus Pmab induced a significantly superior PFS compared with FU/FA alone. If active maintenance therapy is aspired following induction therapy with FU/FA and oxaliplatin plus Pmab, FU/FA plus Pmab appears to be the most favorable option.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“of neurotoxicity) are associated with toxicities that frequently impair the tolerability and the continuation of treatment.(17-21) Therefore, in the preantibody era, maintenance therapy with fluoropyrimidineswas established following induction therapy with fluoropyrimidines and oxaliplatin on the basis of the results…”
BackgroundESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 2×
“Third, the PANAMA trial included subgroups of patients with right-sided primary tumor location, BRAF-mutated tumors, and/or microsatellite instability–high tumors who are not ideal candidates for anti-EGFR antibody–based first-line therapy.(8-10,14,34) Interestingly, right-sided primary tumor location was slightly und…”
BackgroundMethodSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“INTRODUCTION Previously untreated patients with microsatellite-stable metastatic colorectal cancer (mCRC) are typically treated with combinations of fluorouracil and folinic acid (FU/FA) plus either oxaliplatin (FOLFOX) or irinotecan or with all three agents.(1-8) Additionally, monoclonal antibodies targeting either t…”
BackgroundHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citationDuration of adjuvant chemotherapy for stage III colon cancer
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Paul, J., Taieb, J., Souglakos, J., Shi, Q., Kerr, R., Labianca, R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713709 · Cited by 1,092 · cited 2×
“DISCUSSION The development of maintenance therapies is based on the clinical necessity to discontinue or reduce oxaliplatin-based chemotherapies because of toxicity and intolerability (mostly accumulating neurotoxicity).(1,18,19,27) Therefore, maintenance therapy concepts are usually free of oxaliplatin.”
BackgroundPeeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., et al. (2017) · JAMA · doi:10.1001/jama.2017.7105 · Cited by 898
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citation
Research works printed but not linked: 21
- 10.1056/NEJMoa1403108 · DOI · Paper page
- 10.1200/JCO.19.01340 · DOI · Paper page
- 10.1093/annonc/mdx175 · DOI · Paper page
- 10.1016/j.clcc.2014.12.011 · DOI
- 10.1200/JCO.2013.53.2473 · DOI · Paper page
- 10.1200/JCO.2016.34.15_suppl.3504 · DOI · Paper page
- 10.1200/JCO.2009.27.4860 · DOI · Paper page
- 10.1200/JCO.2005.03.0106 · DOI · Paper page
- 10.1002/ijc.32110 · DOI
- 10.1016/S1470-2045(14)70106-8 · DOI
- 10.1016/j.ejca.2018.06.024 · DOI
- 10.1200/JCO.2021.39.3_suppl.15 · doi:10.1200/jco.2021.39.3_suppl.15
- 10.1001/jamaoncol.2019.1467 · DOI · Paper page
- 10.1016/S1470-2045(11)70102-4 · DOI · Paper page
- 10.1016/S0140-6736(14)62004-3 · DOI · Paper page
- 10.1093/annonc/mdv011 · DOI
- 10.1016/j.ejca.2019.07.006 · DOI
- Kurreck A, 2020, J Cancer Res Clin Oncol, 146, 2681, 10.1007/s00432-020-03257-z · DOI
- 10.1016/j.ejca.2015.06.116 · DOI · Paper page
- 10.1016/j.ctrv.2021.102226 · DOI
- 10.1001/jamaoncol.2019.4489 · DOI
Cited by
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Stahler, A., Hoppe, B., Na, I.-K., Keilholz, L., Müller, L., Karthaus, M., Fruehauf, S., Graeven, U., Fischer von Weikersthal, L., Goekkurt, E., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02582 · Cited by 16
Self-citationAbbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
“Trials such as VALENTINO and PANAMA show that after an initial course of FOLFOX plus panitumumab, stopping oxaliplatin and continuing with fluoropy-rimidine (fluorouracil/leucovorin) plus panitimumab can help maintain disease control while reducing toxicity [45,46].”
Morano, F., & Pietrantonio, F. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.33488 · Cited by 3
Metadata
- Authors
- Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Kurreck, A., Stahler, A., Held, S., Jarosch, A., Horst, D., Reinacher-Schick, A., Kasper, S., Heinemann, V., Stintzing, S., & Trarbach, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-01-01
- Volume
- 40
- Issue
- 1
- Pages
- 72-82
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3201195457
- Cited by
- 86
- References
- 15
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). https://app.cochat.ai/papers/10.1200/jco.21.01332
- The paper
- Modest, D. P., Karthaus, M., Fruehauf, S., Graeven, U., Müller, L., König, A. O., Fischer von Weikersthal, L., Caca, K., Kretzschmar, A., Goekkurt, E., Haas, S., Kurreck, A., Stahler, A., Held, S., Jarosch, A., Horst, D., Reinacher-Schick, A., Kasper, S., Heinemann, V., . . . Trarbach, T. (2022). Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01332
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.